The definitive directory of gene and cell therapy developers, spanning CAR-T and engineered immune cell therapy, CRISPR and next-generation gene editing, AAV gene therapy, rare disease programs, in vivo delivery platforms, and cell & gene manufacturing. Curated for biotech investors, business development leads, and scientists tracking the CGT landscape.
BioMed Nexus tracks 170 gene and cell therapy companies across 7 categories: CAR-T & immune cell therapy, gene editing & CRISPR, AAV gene therapy, rare disease, in vivo delivery, platform & tools, and autoimmune & other cell therapies. The directory covers the leading CGT developers, including CRISPR Therapeutics, Intellia, Beam, Sarepta, Kite Pharma and Legend Biotech, alongside emerging biotechs. Last updated July 2026
Every listing here is free by name. Add a Verified Listing ($495 per year) with a tagline, website link, and verified badge, or go Featured for your logo, full description, and priority placement at the top of this directory. Data Partners also get a dedicated landing page and a sponsored spotlight in a daily brief reaching about 43,000 recipients.
Featured spots are limited per category.
Right now, every company in this directory is just a name in a database. Featured partners get a full profile with logo, pipeline, modality, backlinks, and priority placement at the very top of this page. Claim the top spot before your competitors do. A Verified Listing is the lighter option: your tagline, website link, and verified badge for $495 per year.
The BioMed Nexus Gene & Cell Therapy Companies Directory is a comprehensive, regularly updated list of gene and cell therapy developers, spanning CAR-T and engineered immune cell therapy, CRISPR and next-generation gene editing, AAV gene therapy, ex vivo rare disease therapies, in vivo delivery platforms, cell and gene therapy manufacturing (CDMO) and tools, and emerging autoimmune cell therapies. It covers approved-therapy leaders alongside clinical- and preclinical-stage biotechs.
Use it to research gene and cell therapy companies by modality, track the competitive landscape, and map CDMO and platform partners. Whether you are a biotech investor evaluating the CGT sector, a business development lead scouting partners, or a scientist tracking modalities, the directory provides structured, current company data. Curated and maintained by the BioMed Nexus editorial team; last updated July 2026.
Companies can claim a free listing by name or add a Verified Listing ($495 per year) with a tagline, website link, and verified badge. Featured Profiles and Data Partners get priority placement, and Data Partners add a dedicated landing page and a sponsored spotlight in the BioMed Nexus daily brief, which reaches about 43,000 recipients per weekday edition. Contact our partnerships team to learn more.
